Key Points
- Heartflow insider Campbell Rogers sold 23,933 shares at an average price of $55.01, generating approximately $1.32 million. The Rule 10b5-1 transaction reduced Rogers’ ownership by 24.58% to 73,453 shares.
- Heartflow shares opened at $57.01, near their 12-month high of $57.74, and the company reported 47.7% year-over-year revenue growth to $64.08 million in its latest quarter. It still posted a net loss, though quarterly EPS of negative $0.07 beat analyst expectations.
- Analyst sentiment remains positive overall, with a consensus “Moderate Buy” rating and an average price target of $48.62, while institutional investors have recently established or increased positions in the stock.
Heartflow, Inc. (NASDAQ:HTFL - Get Free Report) insider Campbell Rogers sold 23,933 shares of the business's stock in a transaction that occurred on Thursday, October 22nd. The shares were sold at an average price of $55.01, for a total value of $1,316,554.33. Following the completion of the sale, the insider owned 73,453 shares of the company's stock, valued at $4,040,649.53. This trade represents a 24.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Campbell Rogers also recently made the following trade(s):
- On Friday, September 18th, Campbell Rogers sold 19,682 shares of Heartflow stock. The shares were sold at an average price of $50.15, for a total value of $987,052.30.
- On Monday, August 17th, Campbell Rogers sold 9,219 shares of Heartflow stock. The stock was sold at an average price of $41.23, for a total value of $380,099.37.
Heartflow Trading Up 0.5%
Shares of HTFL opened at $57.01 on Tuesday. Heartflow, Inc. has a 12-month low of $20.13 and a 12-month high of $57.74. The firm has a market capitalization of $4.96 billion, a P/E ratio of -31.15 and a beta of 2.73. The firm has a 50-day moving average price of $49.38 and a 200 day moving average price of $33.51.
Heartflow (NASDAQ:HTFL - Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.15. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.52%. The company had revenue of $64.08 million for the quarter. The firm's quarterly revenue was up 47.7% compared to the same quarter last year. Equities research analysts predict that Heartflow, Inc. will post -0.75 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Heartflow
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. XXEC Inc. acquired a new position in shares of Heartflow in the second quarter worth about $2,524,764,000. Quantinno Capital Management LP bought a new stake in Heartflow during the first quarter valued at $1,734,000. Sei Investments Co. raised its stake in Heartflow by 342.5% during the first quarter. Sei Investments Co. now owns 67,048 shares of the company's stock worth $1,631,000 after acquiring an additional 51,895 shares during the period. Bank of New York Mellon Corp acquired a new stake in shares of Heartflow during the 2nd quarter worth approximately $19,096,000. Finally, Handelsbanken Fonder AB acquired a new position in shares of Heartflow during the second quarter valued at $910,000.
Analysts Set New Price Targets
HTFL has been the subject of several research reports. Morgan Stanley boosted their target price on Heartflow from $35.00 to $40.00 and gave the company an "equal weight" rating in a report on Friday, August 14th. Weiss Ratings raised Heartflow from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, August 7th. Canaccord Genuity Group upped their target price on shares of Heartflow from $45.00 to $56.00 and gave the stock a "buy" rating in a research report on Tuesday, September 22nd. Robert W. Baird set a $45.00 price target on Heartflow in a research note on Friday, August 14th. Finally, UBS Group began coverage on Heartflow in a research report on Wednesday, September 9th. They set a "neutral" rating and a $55.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $48.62.
Check Out Our Latest Report on Heartflow
About Heartflow
(
Get Free Report)
Heartflow, Inc is a medical technology company that develops artificial intelligence-based tools to help physicians diagnose and manage coronary artery disease. Its platform uses data from coronary computed tomography angiography (CCTA) scans to create personalized, three-dimensional models of a patient's coronary arteries and provide noninvasive assessments of blood flow and disease.
The company's products include Heartflow Analysis, which provides fractional flow reserve computed tomography (FFR-CT) evaluations to help identify potentially significant blockages, as well as tools for assessing coronary plaque and planning treatment.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
